Phase Forward Incorporated (NASDAQ: PFWD), a provider of data management solutions for clinical trials and drug safety, announced today that it will be hosting an analyst day on Tuesday, June 19th, in conjunction with the Drug Information Association’s Annual Meeting in Atlanta, Georgia. The Company will discuss the launch of its new Central Designer(TM) application targeted at the EDC market, and provide demos of this new application, as well as the Company’s InForm(TM) EDC product and CTSD(TM) clinical trials signal detection product.
The Phase Forward presentation will begin at 10:30 a.m. Eastern Time and is expected to last approximately two hours. Phase Forward executives presenting at the event will include:
-- Robert Weiler, Chief Executive Officer
-- Steve Rosenberg, Senior Vice President of R&D and Services
-- Martin Young, Vice President, Corporate Development
-- Robert Quinn, Product Marketing Manager
-- Robbert van Manen, Senior Solutions Consultant
The presentation will be webcast live and will be available by visiting the Investor Relations section of the website at www.phaseforward.com. The webcast will be archived on the Company’s website for 30 days after the presentation ends.
About Phase Forward
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company offers proven solutions for electronic data capture (InForm(TM)), clinical data management (Clintrial(TM)), clinical trials signal detection (CTSD(TM)), strategic pharmacovigilance (WebVDME(TM) and Signal Management), adverse event reporting (Clintrace(TM)) and applied data standards (WebSDM(TM)). In addition, the company provides services in the areas of application implementation, hosting and validation, data integration, business process optimization, safety data management and industry standards. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 250 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, or FDA, GlaxoSmithKline, Harvard Clinical Research Institute, Merck & Co., Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Tibotec, the U.K. Medicines and Healthcare Products Regulatory Agency and Servier. Additional information about Phase Forward is available at www.phaseforward.com.
